Moderna in Discussions to Supply Japan with Doses of its COVID-19 Vaccine Candidate
The vaccine will be supplied by Moderna and distributed in Japan by Takeda Pharmaceutical starting in the first half of 2021 if the vaccine candidate receives regulatory approval.
Moderna announced on Aug. 28, 2020 that it is in discussions with the Ministry of Health, Labour and Welfare of Japan (MHLW) to purchase 40 million or more doses of mRNA-1273, Moderna’s COVID-19 vaccine candidate.
Through the agreement, the vaccine will be supplied by Moderna and distributed in Japan by Takeda Pharmaceutical starting in the first half of 2021 if the vaccine candidate receives regulatory approval, a Moderna press release said.
Source: Moderna
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
